Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00262-007-0293-4.

Title:
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers | Cancer Immunology, Immunotherapy
Description:
p53 mutations are found in up to 30% of breast cancers and peptides derived from over-expressed p53 protein are presented by class I HLA molecules and may act as tumor-associated epitopes in cancer vaccines. A dendritic cell (DC) based p53 targeting vaccine was analyzed in HLA-A2+ patients with progressive advanced breast cancer. DCs were loaded with 3 wild-type and 3 P2 anchor modified HLA-A2 binding p53 peptides. Patients received up to 10 sc vaccinations with 5 × 106 p53-peptide loaded DC with 1–2 weeks interval. Concomitantly, 6 MIU/m2 interleukine-2 was administered sc. Results from a phase II trial including 26 patients with verified progressive breast cancer are presented. Seven patients discontinued treatment after only 2–3 vaccination weeks due to rapid disease progression or death. Nineteen patients were available for first evaluation after 6 vaccinations; 8/19 evaluable patients attained stable disease (SD) or minor regression while 11/19 patients had progressive disease (PD), indicating an effect of p53-specific immune therapy. This was supported by: (1) a positive correlation between p53 expression of tumor and observed SD, (2) therapy induced p53 specific T cells in 4/7 patients with SD but only in 2/9 patients with PD, and (3) significant response associated changes in serum YKL-40 and IL-6 levels identifying these biomarkers as possible candidates for monitoring of response in connection with DC based cancer immunotherapy. In conclusion, a significant fraction of breast cancer patients obtained SD during p53-targeting DC therapy. Data encourage initiation of a randomized trial in p53 positive patients evaluating the impact on progression free survival.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?


Link.springer.com is powered by PLONE.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, google, scholar, pubmed, article, cas, patients, cells, dendritic, breast, cell, immunol, response, clinical, res, human, serum, clin, van, immunotherapy, svane, claesson, advanced, ykl, pedersen, johansen, tumor, vaccination, disease, wildtype, interleukin, nielsen, protein, vaccine, therapy, levels, survival, access, responses, immunother, department, copenhagen, denmark, privacy, cookies, content, biomarkers, johnsen, peptides, hlaa,

Topics {✒️}

p53-derived hla-a2-binding peptides wild-type p53-derived peptide p53-peptide-pulsed dendritic cells melanoma-specific t-cell responses month download article/chapter k-ras-derived peptides survivin-derived ctl epitopes wild-type sequence p53 wild-type p53 protein human connective-tissue cells extracellular signal-regulated kinase p53-specific immune responses p53 tumor-suppressor gene p53-targeting dc therapy macrophage colony-stimulating factor p53-specific immune therapy cytotoxic t-lymphocyte clones full article pdf c-erbb-2 oncoproteins overexpression hla-a2+ patients stable dendritic cells article cancer immunology inge marie svane dendritic cells transduced cancer vaccines expressed p53 protein svane im telomerase peptide vaccination p53 cancer vaccine peptides derived advanced breast cancer increased ctl immunogenicity cancers overexpressing p53 privacy choices/manage cookies article svane metastatic breast carcinoma 3 wild-type recurrent breast cancer human mammary tumors lymphocyte clone recognizing metastatic breast cancer dendritic cells dendritic cell van der bs inducing immune responses von der mh cancer immune therapy dansk kræftforsknings fond cells specific cancer vaccination therapy

Questions {❓}

  • Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
         description:p53 mutations are found in up to 30% of breast cancers and peptides derived from over-expressed p53 protein are presented by class I HLA molecules and may act as tumor-associated epitopes in cancer vaccines. A dendritic cell (DC) based p53 targeting vaccine was analyzed in HLA-A2+ patients with progressive advanced breast cancer. DCs were loaded with 3 wild-type and 3 P2 anchor modified HLA-A2 binding p53 peptides. Patients received up to 10 sc vaccinations with 5 × 106 p53-peptide loaded DC with 1–2 weeks interval. Concomitantly, 6 MIU/m2 interleukine-2 was administered sc. Results from a phase II trial including 26 patients with verified progressive breast cancer are presented. Seven patients discontinued treatment after only 2–3 vaccination weeks due to rapid disease progression or death. Nineteen patients were available for first evaluation after 6 vaccinations; 8/19 evaluable patients attained stable disease (SD) or minor regression while 11/19 patients had progressive disease (PD), indicating an effect of p53-specific immune therapy. This was supported by: (1) a positive correlation between p53 expression of tumor and observed SD, (2) therapy induced p53 specific T cells in 4/7 patients with SD but only in 2/9 patients with PD, and (3) significant response associated changes in serum YKL-40 and IL-6 levels identifying these biomarkers as possible candidates for monitoring of response in connection with DC based cancer immunotherapy. In conclusion, a significant fraction of breast cancer patients obtained SD during p53-targeting DC therapy. Data encourage initiation of a randomized trial in p53 positive patients evaluating the impact on progression free survival.
         datePublished:2007-02-07T00:00:00Z
         dateModified:2007-02-07T00:00:00Z
         pageStart:1485
         pageEnd:1499
         sameAs:https://doi.org/10.1007/s00262-007-0293-4
         keywords:
            Dendritic cells
            Breast cancer
            p53 peptides
            Immunotherapy
            Biomarkers
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0293-4/MediaObjects/262_2007_293_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0293-4/MediaObjects/262_2007_293_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0293-4/MediaObjects/262_2007_293_Fig3_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Inge Marie Svane
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:Copenhagen University Hospital
                     address:
                        name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Anders E. Pedersen
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julia S. Johansen
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Department of Rheumatology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hans E. Johnsen
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dorte Nielsen
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Claus Kamby
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Svend Ottesen
               affiliation:
                     name:Roskilde Hospital
                     address:
                        name:Department of Oncology, Roskilde Hospital, Roskilde, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva Balslev
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Department of Pathology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva Gaarsdal
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kirsten Nikolajsen
               affiliation:
                     name:Copenhagen University Hospital
                     address:
                        name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mogens H. Claesson
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
      description:p53 mutations are found in up to 30% of breast cancers and peptides derived from over-expressed p53 protein are presented by class I HLA molecules and may act as tumor-associated epitopes in cancer vaccines. A dendritic cell (DC) based p53 targeting vaccine was analyzed in HLA-A2+ patients with progressive advanced breast cancer. DCs were loaded with 3 wild-type and 3 P2 anchor modified HLA-A2 binding p53 peptides. Patients received up to 10 sc vaccinations with 5 × 106 p53-peptide loaded DC with 1–2 weeks interval. Concomitantly, 6 MIU/m2 interleukine-2 was administered sc. Results from a phase II trial including 26 patients with verified progressive breast cancer are presented. Seven patients discontinued treatment after only 2–3 vaccination weeks due to rapid disease progression or death. Nineteen patients were available for first evaluation after 6 vaccinations; 8/19 evaluable patients attained stable disease (SD) or minor regression while 11/19 patients had progressive disease (PD), indicating an effect of p53-specific immune therapy. This was supported by: (1) a positive correlation between p53 expression of tumor and observed SD, (2) therapy induced p53 specific T cells in 4/7 patients with SD but only in 2/9 patients with PD, and (3) significant response associated changes in serum YKL-40 and IL-6 levels identifying these biomarkers as possible candidates for monitoring of response in connection with DC based cancer immunotherapy. In conclusion, a significant fraction of breast cancer patients obtained SD during p53-targeting DC therapy. Data encourage initiation of a randomized trial in p53 positive patients evaluating the impact on progression free survival.
      datePublished:2007-02-07T00:00:00Z
      dateModified:2007-02-07T00:00:00Z
      pageStart:1485
      pageEnd:1499
      sameAs:https://doi.org/10.1007/s00262-007-0293-4
      keywords:
         Dendritic cells
         Breast cancer
         p53 peptides
         Immunotherapy
         Biomarkers
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0293-4/MediaObjects/262_2007_293_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0293-4/MediaObjects/262_2007_293_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0293-4/MediaObjects/262_2007_293_Fig3_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Inge Marie Svane
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:Copenhagen University Hospital
                  address:
                     name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Anders E. Pedersen
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julia S. Johansen
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Department of Rheumatology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hans E. Johnsen
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dorte Nielsen
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Claus Kamby
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Svend Ottesen
            affiliation:
                  name:Roskilde Hospital
                  address:
                     name:Department of Oncology, Roskilde Hospital, Roskilde, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva Balslev
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Department of Pathology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva Gaarsdal
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kirsten Nikolajsen
            affiliation:
                  name:Copenhagen University Hospital
                  address:
                     name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mogens H. Claesson
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Copenhagen University Hospital
      address:
         name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Department of Rheumatology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Roskilde Hospital
      address:
         name:Department of Oncology, Roskilde Hospital, Roskilde, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Department of Pathology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Copenhagen University Hospital
      address:
         name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Inge Marie Svane
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:Copenhagen University Hospital
            address:
               name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Anders E. Pedersen
      affiliation:
            name:University of Copenhagen
            address:
               name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Julia S. Johansen
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Department of Rheumatology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Hans E. Johnsen
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Dorte Nielsen
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Claus Kamby
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Svend Ottesen
      affiliation:
            name:Roskilde Hospital
            address:
               name:Department of Oncology, Roskilde Hospital, Roskilde, Denmark
               type:PostalAddress
            type:Organization
      name:Eva Balslev
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Department of Pathology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Eva Gaarsdal
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Kirsten Nikolajsen
      affiliation:
            name:Copenhagen University Hospital
            address:
               name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Mogens H. Claesson
      affiliation:
            name:University of Copenhagen
            address:
               name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
      name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
      name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
      name:Department of Rheumatology, Copenhagen University Hospital, Herlev, Denmark
      name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
      name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
      name:Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
      name:Department of Oncology, Roskilde Hospital, Roskilde, Denmark
      name:Department of Pathology, Copenhagen University Hospital, Herlev, Denmark
      name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
      name:Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark
      name:Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(200)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.43s.